Life sciences investment firm Malin has said it will seek to raise an additional €42m via a private placement.
The Dublin-listed company raised €330m in one of Europe's biggest life science stock market debuts in March.
It said it will sell the shares at €10.99, above the €10 per-share issue price in March and said expressions of interest had already been received from existing shareholders.
Malin also announced an $80m investment in UK life sciences company Immunocore, which will be financed through its existing cash resources.
It is joining other companies, including Eli Lilly and Woodford Investment Management, in investing a total of $320m in Immunocore.
Oxford-based Immunocore said it will use the proceeds to accelerate its pipeline of new next-generation cancer drugs that fight tumours in ways antibody drugs cannot.
"From a Malin shareholder perspective, the opportunity to be involved in Immunocore is a significant one, and one that we have to take very seriously," Malin's chief executive Adrian Howd, who will join the Immunocore board, told Reuters.
"This has probably been one of the most overly subscribed and highly validated rounds I've ever seen for a relatively early stage biotech company. We have really landed something here that is of huge potential value."